Genetic variation in the plasmodium falciparum circumsporozoite protein in india and its relevance to RTS,S malaria vaccine

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Zeeshan, Mohammad ^a   Alam, Mohammad Tauqeer ^a   Vinayak, Sumiti ^a   Bora, Hema ^a   Tyagi, Rupesh Kumar ^a   Alam, Mohd Shoeb ^a   Choudhary, Vandana ^a   Mittra, Pooja ^a   Lumb, Vanshika ^a   Bharti, Praveen Kumar ^b   Udhayakumar, Venkatachalam ^c   Singh, Neeru ^b   Jain, Vidhan ^b   Singh, Pushpendra Pal ^b   Sharma, Yagya Dutta ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Regional Medical Research Centre for Tribals   (India)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; EPITOPE; MALARIA VACCINE; RTS,S VACCINE; UNCLASSIFIED DRUG;

AFRICA; ALLELE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; ASIA; CARBOXY TERMINAL SEQUENCE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETIC DATABASE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; POPULATION GENETICS; PROSPECTIVE STUDY; SOUTH AMERICA; T LYMPHOCYTE;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; CHILD; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC VARIATION; GENOTYPE; GEOGRAPHY; HAPLOTYPES; HUMANS; INDIA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MOLECULAR SEQUENCE DATA; PHYLOGENY; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROTOZOAN PROTEINS; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; YOUNG ADULT;

EID: 84865094484     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043430     Document Type: Article

References (58)

1. WHO (2010) World malaria report, World Health Organization, Geneva.
2. Crompton PD, Pierce SK, Miller LH, (2010) Advances and challenges in malaria vaccine development. J Clin Invest 120: 4168-4178.
3. Casares S, Brumeanu TD, Richie TL, (2010) The RTS,S malaria vaccine. Vaccine 28: 4880-4894.
4. Enea V, Ellis J, Zavala F, Arnot DE, Asavanich A, et al. (1984) DNA cloning of Plasmodium falciparum circumsporozoite gene: amino acid sequence of repetitive epitope. Science 225: 628-630.
5. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, et al. (1995) Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171: 1576-1585.
6. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, et al. (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336: 86-91.
7. Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, et al. (2008) Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26: 2191-2202.
8. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, et al. (2009) Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 200: 337-346.
9. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr, et al. (2007) A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine 25: 5359-5366.
10. Leach A, Vekemans J, Lievens M, Ofori-Anyinam O, Cahill C, et al. (2011) Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J 10: 224.
11. Aide P, Dobano C, Sacarlal J, Aponte JJ, Mandomando I, et al. (2011) Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine 29: 6059-6067.
12. Aide P, Aponte JJ, Renom M, Nhampossa T, Sacarlal J, et al. (2010) Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS One 5: e13838.
13. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, et al. (2011) Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 11: 102-109.
14. Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, et al. (2011) Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 11: 741-749.
15. Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, et al. (2010) Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 202: 1076-1087.
16. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, et al. (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365: 1863-1875.
17. Malariavaccine website. Available: http://www.malariavaccine.org/malvac-roadmap.php. Accessed 2012 July 26.
18. Hughes AL, (1991) Circumsporozoite protein genes of malaria parasites (Plasmodium spp.): evidence for positive selection on immunogenic regions. Genetics 127: 345-353.
19. Putaporntip C, Jongwutiwes S, Hughes AL, (2008) Differential selective pressures on the merozoite surface protein 2 locus of Plasmodium falciparum in a low endemic area. Gene 427: 51-57.
20. Garg S, Alam MT, Das MK, Dev V, Kumar A, et al. (2007) Sequence diversity and natural selection at domain I of the apical membrane antigen 1 among Indian Plasmodium falciparum populations. Malar J 6: 154.
21. Tanabe K, Sakihama N, Kaneko A, (2004) Stable SNPs in malaria antigen genes in isolated populations. Science 303: 493.
22. Escalante AA, Grebert HM, Isea R, Goldman IF, Basco L, et al. (2002) A study of genetic diversity in the gene encoding the circumsporozoite protein (CSP) of Plasmodium falciparum from different transmission areas-XVI. Asembo Bay Cohort Project. Mol Biochem Parasitol 125: 83-90.
23. Escalante AA, Lal AA, Ayala FJ, (1998) Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics 149: 189-202.
24. Conway DJ, (1997) Natural selection on polymorphic malaria antigens and the search for a vaccine. Parasitol Today 13: 26-29.
25. Barry AE, Schultz L, Buckee CO, Reeder JC, (2009) Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. PLoS One 4: e8497.
26. Hill AV, Elvin J, Willis AC, Aidoo M, Allsopp CE, et al. (1992) Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360: 434-439.
27. Udhayakumar V, Ongecha JM, Shi YP, Aidoo M, Orago AS, et al. (1997) Cytotoxic T cell reactivity and HLA-B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults. Eur J Immunol 27: 1952-1957.
28. Vinayak S, Mittra P, Sharma YD, (2006) Wide variation in microsatellite sequences within each Pfcrt mutant haplotype. Mol Biochem Parasitol 147: 101-108.
29. Hall TA, (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41: 95-98.
30. Nicholas KB, Nicholas HB, Deerfield DW, (1997) GeneDoc: Analysis and visualization of genetic variation. EMBNEWNEWS 4: 14.
31. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R, (2003) DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics 19: 2496-2497.
32. Tamura K, Dudley J, Nei M, Kumar S, (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
33. Nei M, Gojobori T, (1986) Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 3: 418-426.
34. Fu YX, Li WH, (1993) Statistical tests of neutrality of mutations. Genetics 133: 693-709.
35. Tajima F, (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 123: 585-595.
36. Aley SB, Bates MD, Tam JP, Hollingdale MR, (1986) Synthetic peptides from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium knowlesi recognize the human hepatoma cell line HepG2-A16 in vitro. J Exp Med 164: 1915-1922.
37. Shi YP, Udhayakumar V, Alpers MP, Povoa MM, Oloo AJ, et al. (1993) Natural antibody responses against the non-repeat-sequence-based B-cell epitopes of the Plasmodium falciparum circumsporozoite protein. Infect Immun 61: 2425-2433.
38. Putaporntip C, Jongwutiwes S, Hughes AL, (2009) Natural selection maintains a stable polymorphism at the circumsporozoite protein locus of Plasmodium falciparum in a low endemic area. Infect Genet Evol 9: 567-573.
39. Jongwutiwes S, Tanabe K, Hughes MK, Kanbara H, Hughes AL, (1994) Allelic variation in the circumsporozoite protein of Plasmodium falciparum from Thai field isolates. Am J Trop Med Hyg 51: 659-668.
40. Jongwutiwes S, Putaporntip C, Hughes AL (2010) Bottleneck effects on vaccine-candidate antigen diversity of malaria parasites in Thailand. Vaccine.
41. Weedall GD, Preston BM, Thomas AW, Sutherland CJ, Conway DJ, (2007) Differential evidence of natural selection on two leading sporozoite stage malaria vaccine candidate antigens. Int J Parasitol 37: 77-85.
42. Zakeri S, Avazalipoor M, Mehrizi AA, Djadid ND, Snounou G, (2007) Restricted T-cell epitope diversity in the circumsporozoite protein from Plasmodium falciparum populations prevalent in Iran. Am J Trop Med Hyg 76: 1046-1051.
43. Rathore D, Sacci JB, de la Vega P, McCutchan TF, (2002) Binding and invasion of liver cells by Plasmodium falciparum sporozoites. Essential involvement of the amino terminus of circumsporozoite protein. J Biol Chem 277: 7092-7098.
44. Ancsin JB, Kisilevsky R, (2004) A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein: significance for malarial sporozoite attachment to hepatocytes. J Biol Chem 279: 21824-21832.
45. Rathore D, Nagarkatti R, Jani D, Chattopadhyay R, de la Vega P, et al. (2005) An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J Biol Chem 280: 20524-20529.
46. Bongfen SE, Ntsama PM, Offner S, Smith T, Felger I, et al. (2009) The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27: 328-335.
47. Roggero MA, Filippi B, Church P, Hoffman SL, Blum-Tirouvanziam U, et al. (1995) Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Mol Immunol 32: 1301-1309.
48. Alloueche A, Milligan P, Conway DJ, Pinder M, Bojang K, et al. (2003) Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg 68: 97-101.
49. Enosse S, Dobano C, Quelhas D, Aponte JJ, Lievens M, et al. (2006) RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials 1: e5.
50. Waitumbi JN, Anyona SB, Hunja CW, Kifude CM, Polhemus ME, et al. (2009) Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS One 4: e7849.
51. Kumkhaek C, Phra-Ek K, Renia L, Singhasivanon P, Looareesuwan S, et al. (2005) Are extensive T cell epitope polymorphisms in the Plasmodium falciparum circumsporozoite antigen, a leading sporozoite vaccine candidate, selected by immune pressure? J Immunol 175: 3935-3939.
52. de Stricker K, Vuust J, Jepsen S, Oeuvray C, Theisen M, (2000) Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum. Mol Biochem Parasitol 111: 123-130.
53. Yoshida N, Di Santi SM, Dutra AP, Nussenzweig RS, Nussenzweig V, et al. (1990) Plasmodium falciparum: restricted polymorphism of T cell epitopes of the circumsporozoite protein in Brazil. Exp Parasitol 71: 386-392.
54. Chenet SM, Branch OH, Escalante AA, Lucas CM, Bacon DJ, (2008) Genetic diversity of vaccine candidate antigens in Plasmodium falciparum isolates from the Amazon basin of Peru. Malar J 7: 93.
55. Jalloh A, van Thien H, Ferreira MU, Ohashi J, Matsuoka H, et al. (2006) Sequence variation in the T-cell epitopes of the Plasmodium falciparum circumsporozoite protein among field isolates is temporally stable: a 5-year longitudinal study in southern Vietnam. J Clin Microbiol 44: 1229-1235.
56. Doolan DL, Saul AJ, Good MF, (1992) Geographically restricted heterogeneity of the Plasmodium falciparum circumsporozoite protein: relevance for vaccine development. Infect Immun 60: 675-682.
57. Alloueche A, Silveira H, Conway DJ, Bojang K, Doherty T, et al. (2000) High-throughput sequence typing of T-cell epitope polymorphisms in Plasmodium falciparum circumsporozoite protein. Mol Biochem Parasitol 106: 273-282.
58. Jalloh A, Jalloh M, Matsuoka H, (2009) T-cell epitope polymorphisms of the Plasmodium falciparum circumsporozoite protein among field isolates from Sierra Leone: age-dependent haplotype distribution? Malar J 8: 120.